• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

创建改良版剑桥多病种评分以预测 16 岁以上人群的死亡率:模型的建立和验证。

Creating a Modified Version of the Cambridge Multimorbidity Score to Predict Mortality in People Older Than 16 Years: Model Development and Validation.

机构信息

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.

Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom.

出版信息

J Med Internet Res. 2024 Aug 26;26:e56042. doi: 10.2196/56042.

DOI:10.2196/56042
PMID:39186368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11384182/
Abstract

BACKGROUND

No single multimorbidity measure is validated for use in NHS (National Health Service) England's General Practice Extraction Service Data for Pandemic Planning and Research (GDPPR), the nationwide primary care data set created for COVID-19 pandemic research. The Cambridge Multimorbidity Score (CMMS) is a validated tool for predicting mortality risk, with 37 conditions defined by Read Codes. The GDPPR uses the more internationally used Systematized Nomenclature of Medicine clinical terms (SNOMED CT). We previously developed a modified version of the CMMS using SNOMED CT, but the number of terms for the GDPPR data set is limited making it impossible to use this version.

OBJECTIVE

We aimed to develop and validate a modified version of CMMS using the clinical terms available for the GDPPR.

METHODS

We used pseudonymized data from the Oxford-Royal College of General Practitioners Research and Surveillance Centre (RSC), which has an extensive SNOMED CT list. From the 37 conditions in the original CMMS model, we selected conditions either with (1) high prevalence ratio (≥85%), calculated as the prevalence in the RSC data set but using the GDPPR set of SNOMED CT codes, divided by the prevalence included in the RSC SNOMED CT codes or (2) conditions with lower prevalence ratios but with high predictive value. The resulting set of conditions was included in Cox proportional hazard models to determine the 1-year mortality risk in a development data set (n=500,000) and construct a new CMMS model, following the methods for the original CMMS study, with variable reduction and parsimony, achieved by backward elimination and the Akaike information stopping criterion. Model validation involved obtaining 1-year mortality estimates for a synchronous data set (n=250,000) and 1-year and 5-year mortality estimates for an asynchronous data set (n=250,000). We compared the performance with that of the original CMMS and the modified CMMS that we previously developed using RSC data.

RESULTS

The initial model contained 22 conditions and our final model included 17 conditions. The conditions overlapped with those of the modified CMMS using the more extensive SNOMED CT list. For 1-year mortality, discrimination was high in both the derivation and validation data sets (Harrell C=0.92) and 5-year mortality was slightly lower (Harrell C=0.90). Calibration was reasonable following an adjustment for overfitting. The performance was similar to that of both the original and previous modified CMMS models.

CONCLUSIONS

The new modified version of the CMMS can be used on the GDPPR, a nationwide primary care data set of 54 million people, to enable adjustment for multimorbidity in predicting mortality in people in real-world vaccine effectiveness, pandemic planning, and other research studies. It requires 17 variables to produce a comparable performance with our previous modification of CMMS to enable it to be used in routine data using SNOMED CT.

摘要

背景

没有单一的多病种衡量标准经过验证可用于 NHS(国家医疗服务体系)英格兰的全科医生提取服务数据用于大流行规划和研究(GDPPR),这是为 COVID-19 大流行研究创建的全国性初级保健数据集。剑桥多病种评分(CMMS)是一种经过验证的预测死亡率风险的工具,其中 37 种疾病由 Read 代码定义。GDPPR 使用更国际化的医学系统术语命名法(SNOMED CT)。我们之前使用 SNOMED CT 开发了 CMMS 的修改版本,但 GDPPR 数据集的术语数量有限,无法使用此版本。

目的

我们旨在使用 GDPPR 可用的临床术语开发和验证 CMMS 的修改版本。

方法

我们使用来自牛津皇家全科医生研究和监测中心(RSC)的假名化数据,该中心拥有广泛的 SNOMED CT 清单。在原始 CMMS 模型中的 37 种疾病中,我们选择了以下两种疾病:(1)高流行率比(≥85%),按照 RSC 数据集中的流行率计算,但使用 GDPPR 的 SNOMED CT 代码集除以 RSC SNOMED CT 代码中包含的流行率;或(2)流行率比较低但预测值较高的疾病。将由此产生的疾病集包含在 Cox 比例风险模型中,以确定开发数据集(n=500,000)中的 1 年死亡率风险,并根据原始 CMMS 研究的方法构建新的 CMMS 模型,通过向后消除和 Akaike 信息停止准则实现变量减少和简约。模型验证涉及为同步数据集(n=250,000)获取 1 年死亡率估计值,并为异步数据集(n=250,000)获取 1 年和 5 年死亡率估计值。我们将性能与原始 CMMS 和我们之前使用 RSC 数据开发的修改后的 CMMS 进行了比较。

结果

初始模型包含 22 种疾病,我们的最终模型包含 17 种疾病。这些疾病与使用更广泛的 SNOMED CT 清单的修改后的 CMMS 中的疾病重叠。对于 1 年死亡率,推导和验证数据集中的区分度都很高(Harrell C=0.92),5 年死亡率略低(Harrell C=0.90)。经过过度拟合调整后,校准是合理的。该性能与原始和以前的修改后的 CMMS 模型相似。

结论

新的 CMMS 修改版本可用于 GDPPR,这是一个拥有 5400 万人口的全国性初级保健数据集,可用于调整多病种在预测现实世界疫苗有效性、大流行规划和其他研究研究中人群死亡率方面的影响。它需要 17 个变量才能产生与我们之前对 CMMS 的修改版本相当的性能,从而能够在常规数据中使用 SNOMED CT 进行使用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/4707c3b0d0ab/jmir_v26i1e56042_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/bffc112fc016/jmir_v26i1e56042_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/ecea0a06b047/jmir_v26i1e56042_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/4707c3b0d0ab/jmir_v26i1e56042_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/bffc112fc016/jmir_v26i1e56042_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/ecea0a06b047/jmir_v26i1e56042_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bd3/11384182/4707c3b0d0ab/jmir_v26i1e56042_fig3.jpg

相似文献

1
Creating a Modified Version of the Cambridge Multimorbidity Score to Predict Mortality in People Older Than 16 Years: Model Development and Validation.创建改良版剑桥多病种评分以预测 16 岁以上人群的死亡率:模型的建立和验证。
J Med Internet Res. 2024 Aug 26;26:e56042. doi: 10.2196/56042.
2
Development of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study.基于 SNOMED CT 的改良剑桥多病种评分的开发:一项基于英国初级保健监测网络的观察性研究。
Br J Gen Pract. 2023 May 25;73(731):e435-e442. doi: 10.3399/BJGP.2022.0235. Print 2023 Jun.
3
Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021.流感和呼吸道病毒监测、疫苗接种情况以及 COVID-19 大流行期间的有效性:2020-2021 年英国初级保健监测系统方案。
JMIR Public Health Surveill. 2021 Feb 19;7(2):e24341. doi: 10.2196/24341.
4
Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England.新型冠状病毒(COVID-19)的出现:皇家全科医师学院研究和监测中心与英国公共卫生署扩展监测所使用的方案。
JMIR Public Health Surveill. 2020 Apr 2;6(2):e18606. doi: 10.2196/18606.
5
The Use of Online Consultation Systems or Remote Consulting in England Characterized Through the Primary Care Health Records of 53 Million People in the OpenSAFELY Platform: Retrospective Cohort Study.利用 OpenSAFELY 平台中 5300 万人的初级保健健康记录,描绘英格兰在线咨询系统或远程咨询的使用情况:回顾性队列研究。
JMIR Public Health Surveill. 2024 Sep 18;10:e46485. doi: 10.2196/46485.
6
Description of COVID-19 patients and mapping nursing data to ICNP 2021 reference set in SNOMED CT.描述 COVID-19 患者并将护理数据映射到 SNOMED CT 中的 ICNP 2021 参考集。
Int Nurs Rev. 2023 Mar;70(1):28-33. doi: 10.1111/inr.12824. Epub 2022 Dec 29.
7
Methodological Issues in Using a Common Data Model of COVID-19 Vaccine Uptake and Important Adverse Events of Interest: Feasibility Study of Data and Connectivity COVID-19 Vaccines Pharmacovigilance in the United Kingdom.使用新冠疫苗接种和重要关注不良事件通用数据模型的方法学问题:英国数据与连接性新冠疫苗药物警戒可行性研究
JMIR Form Res. 2022 Aug 22;6(8):e37821. doi: 10.2196/37821.
8
SNOMED CT Concept Hierarchies for Sharing Definitions of Clinical Conditions Using Electronic Health Record Data.使用电子健康记录数据共享临床病症定义的SNOMED CT概念层次结构。
Appl Clin Inform. 2018 Jul;9(3):667-682. doi: 10.1055/s-0038-1668090. Epub 2018 Aug 29.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
Variation in the recording of diabetes diagnostic data in primary care computer systems: implications for the quality of care.基层医疗计算机系统中糖尿病诊断数据记录的差异:对医疗质量的影响。
Inform Prim Care. 2009;17(2):113-9. doi: 10.14236/jhi.v17i2.723.

引用本文的文献

1
How to assess multimorbidity: a systematic review.如何评估多重疾病:一项系统综述。
Front Public Health. 2025 Mar 27;13:1525593. doi: 10.3389/fpubh.2025.1525593. eCollection 2025.

本文引用的文献

1
AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: The RAVEN cohort study.AZD1222 对合并症或虚弱个体的严重 COVID-19 的疗效:RAVEN 队列研究。
J Infect. 2024 Apr;88(4):106129. doi: 10.1016/j.jinf.2024.106129. Epub 2024 Feb 29.
2
Development of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study.基于 SNOMED CT 的改良剑桥多病种评分的开发:一项基于英国初级保健监测网络的观察性研究。
Br J Gen Pract. 2023 May 25;73(731):e435-e442. doi: 10.3399/BJGP.2022.0235. Print 2023 Jun.
3
Comorbidities, multimorbidity and COVID-19.
合并症、多重疾病与2019冠状病毒病
Nat Med. 2023 Feb;29(2):334-343. doi: 10.1038/s41591-022-02156-9. Epub 2023 Feb 16.
4
Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study.2020 年 10 月至 2021 年 9 月期间,英格兰首次和第二次接种 COVID-19 疫苗后的不良事件:全国疫苗监测平台自身对照病例系列研究。
Euro Surveill. 2023 Jan;28(3). doi: 10.2807/1560-7917.ES.2023.28.3.2200195.
5
Harmonising electronic health records for reproducible research: challenges, solutions and recommendations from a UK-wide COVID-19 research collaboration.协调电子健康记录以实现可重复研究:来自英国 COVID-19 研究合作的挑战、解决方案和建议。
BMC Med Inform Decis Mak. 2023 Jan 16;23(1):8. doi: 10.1186/s12911-022-02093-0.
6
Multimorbidity Patterns and Their Association with Social Determinants, Mental and Physical Health during the COVID-19 Pandemic.多病症模式及其与 COVID-19 大流行期间社会决定因素、心理健康和身体健康的关联。
Int J Environ Res Public Health. 2022 Dec 15;19(24):16839. doi: 10.3390/ijerph192416839.
7
Representativeness, Vaccination Uptake, and COVID-19 Clinical Outcomes 2020-2021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: Cohort Profile Summary.英国牛津-皇家全科医师学院研究和监测网络 2020-2021 年的代表性、疫苗接种率和 COVID-19 临床结局:队列简介摘要。
JMIR Public Health Surveill. 2022 Dec 19;8(12):e39141. doi: 10.2196/39141.
8
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
9
Data saves lives: bottom-up, professionally-led endorsement would increase the chance of success.数据拯救生命:自下而上、由专业人士主导的认可将增加成功的机会。
Br J Gen Pract. 2022 Oct 27;72(724):512-513. doi: 10.3399/bjgp22X720965. Print 2022 Nov.
10
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.在完成初级接种程序和初始加强针接种后出现严重 COVID-19 结局:对英格兰、北爱尔兰、苏格兰和威尔士 3000 万人的全国前瞻性队列研究的汇总分析。
Lancet. 2022 Oct 15;400(10360):1305-1320. doi: 10.1016/S0140-6736(22)01656-7.